Prognostic factors and outcomes in patients with leptomeningeal melanomatosis.
about
Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.Reversible occlusion (on-off) valves in shunted tumor patients.Impact of multimodality approach for patients with leptomeningeal metastases from solid tumorsLeptomeningeal metastases from a primary central nervous system melanoma: a case report and literature review.Primary melanocytic tumors of the central nervous system: Report of two cases and review of literatureMeningeal melanomatosis: a challenge for timely diagnosis.Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case reportHSV-1 as a novel therapy for breast cancer meningeal metastases.Radiation therapy for epithelial ovarian cancer brain metastases: clinical outcomes and predictors of survival.Carcinomatous meningitis: Leptomeningeal metastases in solid tumorsLong-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report.Known and emerging biomarkers of leptomeningeal metastasis and its response to treatment.Neuro-ophthalmologic complications of neoplastic leptomeningeal disease.Primary Intracranial Melanoma with Early Leptomeningeal Spread: A Case Report and Treatment Options Available.Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases.Leptomeningeal disease: current diagnostic and therapeutic strategies.Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma.Primary central nervous system malignant melanoma with leptomeningeal melanomatosis: a case report and review of the literature.Leptomeningeal melanoma-A case series in the era of modern systemic therapy.Leptomeningeal Carcinomatosis Associated with Gall Bladder Carcinoma: a Case Report and Review of Literature.Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab.Chemical meningitis related to intra-CSF liposomal cytarabine.Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges.Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis.Two cases of primary leptomeningeal melanomatosis mimicking subacute meningitis.Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe.Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments.EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours†Ventriculoperitoneal Shunts Equipped with On-Off Valves for Intraventricular Therapies in Patients with Communicating Hydrocephalus due to Leptomeningeal Metastases
P2860
Q30251581-3A41C6B9-AE31-42E4-8146-84F2F6434BA1Q33755797-53D0B8E1-C4FA-40AD-8AF8-99A1DF9CD1E1Q34029965-4BFBF7BE-0A71-4C24-8309-2F70A6A0CFE7Q34085075-C73797CC-161B-4B1B-975C-21EA96684577Q34406042-E1B83B73-749F-4D9F-88AF-770C0E4915E8Q35026061-5EC16CC9-A5C3-4400-B79C-B03E20EF0CB9Q35627248-2A97D523-0B28-411C-8D1D-8B64986458B4Q36616788-549502CF-B39E-4CE7-BF15-B9A54C3A2FF7Q36716765-0215B853-D1AA-45CA-AF84-7D6356406B6DQ36851197-E8AF4B21-5108-47B8-B536-961F60A86F97Q37431085-9F2F5E87-4147-4457-B2AD-75D3A5D99EFBQ37690311-839C0DA2-056C-4535-A614-F7222CE5B4B1Q38155430-0B8F0A85-1830-4DCE-8786-E33FC1D7563FQ38570886-EE7B8B82-9B3E-4B69-ADB6-7404BA02694EQ39126735-40080A88-8497-4DDF-ABAC-234FA833F677Q42700664-1B6D9A51-3244-40BD-A0FA-6EAA37F7F306Q47861254-9609556E-8568-4424-9D13-C4C2B7DD2D8BQ48030006-1C4000A1-D7C3-46BB-A458-2921169D8180Q48246291-14D540DE-3BB7-45F4-88A3-F2E21BFFCF53Q48341674-EBB3BA64-8977-4FCF-9E84-4299A9C2F694Q48553169-8D09A7CA-7018-4F04-B5E9-E11A45C35A6BQ50066702-060C3E22-7CE8-4CCC-936C-BE1071FB73ABQ50125923-C677F108-CFBF-4C31-8CEC-9EFD4CF1148CQ50917300-A84DA9E8-8252-49CF-A4C7-1E1C96219183Q50937051-D8315E09-6D69-4446-BE94-F2B255870405Q52096930-A17DEEED-EFC9-47DD-B438-D4E3F0665FEFQ55327976-4BD7BFF2-C0D0-4503-83F1-AE529C524389Q57578829-6A5DB196-EFB8-4F21-BEBA-46BFE9651D75Q58780721-3C6256D0-F44A-4CD3-BDA9-34D56F2EEFD8
P2860
Prognostic factors and outcomes in patients with leptomeningeal melanomatosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prognostic factors and outcomes in patients with leptomeningeal melanomatosis.
@en
Prognostic factors and outcomes in patients with leptomeningeal melanomatosis.
@nl
type
label
Prognostic factors and outcomes in patients with leptomeningeal melanomatosis.
@en
Prognostic factors and outcomes in patients with leptomeningeal melanomatosis.
@nl
prefLabel
Prognostic factors and outcomes in patients with leptomeningeal melanomatosis.
@en
Prognostic factors and outcomes in patients with leptomeningeal melanomatosis.
@nl
P2093
P2860
P1433
P1476
Prognostic factors and outcomes in patients with leptomeningeal melanomatosis.
@en
P2093
Kenneth R Hess
Laura Harstad
Morris D Groves
P2860
P304
P356
10.1215/15228517-2008-062
P577
2008-08-14T00:00:00Z